Beyond AI Predictions: Identifying Early Rare Disease Patients Through Real-Patient-Evidence Data
Many patient identification strategies rely on AI-generated probabilities, digital signals or estimated cohorts. But a probability is not a real patient. This session introduces a fundamentally different approach.
subrosa OmicsAI’s clinical patient identification programs are built on our proprietary global repositories of rare disease patients — genetically confirmed, sourced from real clinical diagnostics, not from algorithmic predictions. We demonstrate how our rare disease scientists from 29 offices across US, Europe, China, APAC, CIS, GCC and LATAM run the clinical studies aligned with your medical team. By recruiting new cohorts in a unique way, patients are detected years earlier than today’s standards.
Hitting a precisely calculated success rate. Proven in more than 50 worldwide projects. Published. Identification without access is only one slide in a deck. Holistic patient access by subrosa OmicsAI accelerates outcomes. We keep both physicians & patients engaged across the full clinical journey through sustained communication — ensuring that patients receive treatment & stay adherent, even in markets without product authorizations, via individual named patient programs.
